Drugs / iPD1 CD19 eCAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03208556 | Jun 2017 → Jun 2019 | B-cell non-Hodgkin lymphoma | Peking University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iPD1 CD19 eCAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03208556 ↗ |
| Modality | Cell therapy | “iPD1 CD19 eCAR T cells is an enhanced version of the classical 2nd generation anti-CD19 4-1BB-costimulatory chimeric antigen receptor engineered T cells” NCT03208556 ↗ |
| Target | CD19 | “anti-CD19 4-1BB-costimulatory chimeric antigen receptor engineered T cells” NCT03208556 ↗ |